

2022 eCQM Flow eCQM Identifier: CMS347v5

NOTE: This flow diagram represents an overview of population criteria requirements. **Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.**

Statin Therapy for the Prevention and Treatment of Cardiovascular Disease


Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

*All patients who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR

*Patients aged ≥ 20 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR


*Patients aged 40-75 years with a diagnosis of diabetes.

This eCQM is a patient-based measure




2022 eCQM Flow
eCQM Identifier: CMS347v

Statin Therapy for the Prevention and Treatment of
Cardiovascular Disease




2022 eCQM Flow
eCQM Identifier: CMS347v5


Statin Therapy for the Prevention and Treatment of
Cardiovascular Disease





2022 eCQM Flow
eCQM Identifier: CMS347v5



Statin Therapy for the Prevention and Treatment of Cardiovascular Disease








2022 eCQM Flow
eCQM Identifier: CMS347v5

Statin Therapy for the Prevention and Treatment of
Cardiovascular Disease



Sample Calculation:

Performance Rate* (Population 1, 2, and 3) =

Numerator 1 ($a^1 + a^2 + a^3 = 120$ patients)

Denominator ($b^1 + b^2 + b^3 = 300$ patients) - Denominator Exclusions ($x^1 + x^2 + x^3 = 60$ patients) - Denominator Exceptions ($c^1 + c^2 + c^3 = 60$ patients)

$$= \frac{120}{180} = 67\%$$

* This eCQM is intended to have one performance rate

eCQM Identifier: CMS347v5**eCQM Title: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease**

NOTE: This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

Description: Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

*All patients who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR

*Patients aged ≥ 20 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR

*Patients aged 40-75 years with a diagnosis of diabetes.

This eCQM is a patient-based measure.

eCQM Flow Narrative**Initial Population 1**

Start by identifying the Initial Population 1, which includes all patients who were previously diagnosed with or currently have an active diagnosis of clinical ASCVD, including an ASCVD procedure.

Denominator 1

The Denominator 1 is the same as Initial Population 1. In the sample calculation provided at the end of the eCQM flow, Denominator 1 is equal to 100 patients.

Denominator Exclusions 1

The Denominator Exclusions 1 criteria identify a subset of the Denominator 1 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 1 are equal to 20 patients.

Numerator 1

The Numerator 1 criteria identify a subset of the Denominator 1 population (that did not meet the Denominator Exclusions 1 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, Numerator 1 is equal to 40 patients.

Denominator Exceptions 1

The Denominator Exceptions 1 criteria identify patients from the Denominator 1 that did not meet the Denominator Exclusions 1 or Numerator 1 population criteria due to an adverse reaction, such as an allergy to statin medication at any time during the measurement period, or a statin associated muscle symptom during the measurement period; or an order for or receiving palliative care or hospice care before the end of the measurement period; or an active diagnosis of hepatitis A, hepatitis B, liver

disease, or end-stage renal disease (ESRD) at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 1 are equal to 20 patients.

Initial Population 2

Start by identifying the Initial Population 2, which includes patients 20 years and older at the beginning of the measurement period who have ever had a laboratory result of LDL-C ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia without current or prior history of clinical ASCVD or ASCVD procedure.

Denominator 2

The Denominator 2 criteria is the same as Initial Population 2. In the sample calculation provided at the end of the eCQM flow, Denominator 2 is equal to 100 patients.

Denominator Exclusions 2

The Denominator Exclusions 2 criteria identify a subset of the Denominator 2 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 2 are equal to 20 patients.

Numerator 2

The Numerator 2 criteria identify a subset of the Denominator 2 population (that did not meet the Denominator Exclusions 2 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, Numerator 2 is equal to 40 patients.

Denominator Exceptions 2

The Denominator Exceptions 2 criteria identify patients from the Denominator 2 that did not meet the Denominator Exclusions 2 or Numerator 2 population criteria due to an adverse reaction, such as an allergy to statin medication at any time during the measurement period, or a statin associated muscle symptom during the measurement period; or an order for or receiving palliative care or hospice care before the end of the measurement period; or an active diagnosis of hepatitis A, hepatitis B, liver disease, or end-stage renal disease (ESRD) at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 2 are equal to 20 patients.

Initial Population 3

Start by identifying the Initial Population 3, which includes patients aged 40 to 75 years at the beginning of the measurement period with Type 1 or Type 2 diabetes without a current or prior history of clinical ASCVD or ASCVD procedure; or without a laboratory result of LDL-C ≥ 190 mg/dL or without a previously or current diagnosis of familial hypercholesterolemia.

Denominator 3

The Denominator 3 criteria is the same as Initial Population 3. In the sample calculation provided at the end of the eCQM flow, Denominator 3 is equal to 100 patients.

Denominator Exclusions 3

The Denominator Exclusions 3 criteria identify a subset of the Denominator 3 population by excluding patients who are pregnant at any time during the measurement period, patients who are breastfeeding

at any time during the measurement period, and patients who have an active diagnosis of rhabdomyolysis at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 3 are equal to 20 patients.

Numerator 3

The Numerator 3 criteria identify a subset of the Denominator 3 population (that did not meet the Denominator Exclusions 3 criteria) by including patients who were ordered statin therapy during the measurement period or who were actively taking statin therapy any time during the measurement period.. In the sample calculation provided at the end of the eCQM flow, Numerator 3 is equal to 40 patients.

Denominator Exceptions 3

The Denominator Exceptions 3 criteria identify patients from the Denominator 3 that did not meet the Denominator Exclusions 3 or Numerator 3 population criteria due to an adverse reaction, such as an allergy to statin medication at any time during the measurement period, or a statin associated muscle symptom during the measurement period; or an order for or receiving palliative care or hospice care before the end of the measurement period; or an active diagnosis of hepatitis A, hepatitis B, liver disease, or end-stage renal disease (ESRD) at any time during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions 3 are equal to 20 patients.

Sample Calculation

A sample calculation is provided to help determine how the measure performance rate is derived. The measure performance rate is calculated by summing Numerator 1, Numerator 2, and Numerator 3 (total equals 120 patients) then dividing by the difference between of the sum of the Denominators (Denominator 1, Denominator 2, and Denominator 3) and the sum of the Denominator Exclusions (Denominator Exclusions 1, Denominator Exclusions 2, and Denominator Exclusions 3) and the sum of the Denominator Exceptions (Denominator Exceptions 1, Denominator Exceptions 2, and Denominator Exceptions 3) (total equals 180 patients), which is equal to a score of 67 percent.